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Hepatocellular carcinoma (HCC) may develop according to two major pathways, one involving HBV infection and TP53
mutation and the other characterized by HCV infection and CTNNB1 mutation. We have investigated HBV/HCV infections and
TP53/CTNNB1 mutations in 26 HCC patients from Thailand. HBV DNA (genotype B or C) was detected in 19 (73%) of the cases,
including 5 occult infections and 3 coinfections with HCV. TP53 and CTNNB1 mutations were not mutually exclusive, and most
of TP53 mutations were R249S, suggesting a signiﬁcant impact of aﬂatoxin-induced mutagenesis in HCC development.
1.Introduction
With over 600 000 new cases per year, hepatocellular
carcinoma (HCC) is the 5th most common cancer and
the 3rd cause of cancer mortality worldwide. Over 80% of
the cases occur in non-Western countries, in particular in
South-Eastern Asia [1]. The main risk factors are chronic
infections by Hepatitis B (HBV) or C Viruses (HCV),
alcohol, iron overload, and dietary exposure to aﬂatoxin, a
class of mycotoxins contaminating traditional foodstuﬀ in
tropical countries. In South-Eastern Asia, HCC often occurs
in a background of endemic HBV chronicity in conjunction
withaﬂatoxinexposure. ThelatterisclassiﬁedIARC Group1
carcinogen for the liver and causes an inactivating mutation
at codon 249 of the TP53 tumor suppressor gene, inducing
the substitution of an arginine by a serine (R249S mutation)
[2–7].
The mechanisms by which HBV contributes to liver
cancer are multiple, complex, and far from being fully
understood [8]. In brief, three main eﬀects can be distin-
guished. First, chronic infection induces inﬂammation and
deregulation of the physiological balance between liver cell
proliferation, diﬀerentiation and apoptosis. This disrupted
state often leads to cirrhosis, a precursor of HCC. Second,
early in the carcinogenic process, HBV DNA becomes
integrated in the host cell genome, potentially acting as
an insertional mutagen to deregulate adjacent oncogenes
or tumor suppressors. Third, HBV expresses proteins such
as HBx that interacts with a variety of cell components,
aﬀecting many aspects of transcription, proliferation, or2 Hepatitis Research and Treatment
survival. The contribution of each of the above mechanisms
depends on the host immune response, the synergic eﬀects
of environmental factors, and the molecular characteristics
of the strain of HBV involved. Eight major HBV genotypes
have been identiﬁed (genotypes A to H), characterizing
groupsofvirusesthatshowlessthan8%sequencedivergence
between them. These genotypes diﬀer by their geographic
and ethnic distribution and their pathogenicity [9–11]. In
South-Eastern Asia, the predominant genotypes are B and
C, in contrast with, for example, genotype A in Northwest
Europe and North America, genotype D in Southern Europe
and the Middle East, and genotype E in West Africa. Disease
severity has also been shown to be associated with mutation
intheBasalCorePromoter(BCP)regionoftheviralgenome,
resulting in a double base substitution (G1762A/A1764T)
[12].
Hepatocarcinogenesis is accompanied by genetic and
epigenetic alterations at multiple loci, the most frequent
of which are inactivating mutations in TP53 (encoding
the p53 protein, in 20 to 80% of the cases depending
upon geographic and exposure contexts) and activating
mutations in the N-terminus of CTNNB1 (encoding the
transcription factor β-catenin, in 10 to 30% of the cases)
[13–17]. Based on the analysis of 137 cases of HCC from
France and China, Laurent-Puig et al. [18]h a v ep r o p o s e da
model that distinguishes two main pathways of HCC, one
characterized by chromosome instability, TP53 mutations,
Axin 1 mutations, HBV infection, poor diﬀerentiation, and
poorprognosis,andtheothercharacterizedbychromosomal
stability, CTNNB1 mutations, absence of HBV, and tendency
to form large tumors. However, it is not known whether this
general model also applies to HCC from other geographic
areas [14, 15, 18–22].
With incidences (Age-Standardized Rates) of liver and
bile duct cancers of 33.4 in males and 12.3 in females,
Thailand is a region with intermediate incidence of liver
cancer. About 40 to 50% of histologically diagnosed cases are
cholangiocarcinomas, which is predominant in the North-
East region. The main risk factors identiﬁed for HCC are
chronic HBV infection and alcohol drinking, whereas the
role of HCV appears modest and there is no signiﬁcant asso-
ciation with aﬂatoxin exposure as determined by measuring
aﬂatoxin-albumin adducts in the serum. Here we describe
the patterns of mutations in TP53 and CTNNB1 and of
infection by HBV and HCV in 26 cases of primary HCC
from Thailand. We found HBV DNA (genotype B or C) in
19 (73%) of the cases, including 5 occult infections and 3 co-
infections with HCV. Furthermore, we found that TP53 and
CTNNB1 mutations were not mutually exclusive, and that
most of TP53 mutations were R249S, suggesting a signiﬁcant
impact of mutagenesis by aﬂatoxin.
2.MaterialsandMethods
2.1. Patients and Tissues. Patients were recruited and speci-
mens were obtained in the context of a study on the etiology
of HCC that took place at the National Cancer Institute in
Bangkok from 1987 to 1995. The basis for HCC diagnosis
Table 1: Clinicopathological data of HCC cases.
Frequency (%)
Age (n = 24)
≥50 9 (37.5)
<50 15 (62.5)
Mean age ± SD 46 ± 13
Gender (n = 24)
male 20 (83.3)
female 4 (16.7)
HBsAg status (n = 23)
Positive 13 (56.5)
Negative 10 (43.5)




METAVIR Score of NT tissues (n = 20)
Activity < 2 16 (80)
Activity ≥ 2 4 (20)
Fibrosis < 2 5 (25)
Fibrosis ≥ 2 15 (75)
HCC morphology (n = 26)
Trabecular type 18 (69.3)
Pleiomorphic type 3 (11.5)
Pseudo-glandular type 2 (7.7)
Necrotic tissue 3 (11.5)
T = tumor, NT = nontumoral tissue.
was an algorithm including clinical features, biochemistry
(Alpha-fetoprotein levels) and imaging (ultrasonography).
When conﬁrmed by histopathology, this algorithm was
found to be 95% speciﬁc for the detection of HCC. Of
all cases of liver cancer detected during this period, 26
were surgically removed, snap-frozen, and bio-banked after
patient’s informed consent. The case series consisted of
surgical resection pairs of tumor tissue (T) and nontumor
tissue (NT) (the latter were available for 22/26 patients).
Snap-frozen samples were stored at −80◦C, transferred to
IARC and analyzed according to a protocol approved by
IARC Institutional Review Board. Histopathological staging
and grading was performed according to Edmondson-
Steiner.Theclinicopathologicalcharacteristicsofthepatients
are summarized in Table 1 and in Supplementary Table S1
available online at doi:10.1155/2011/697162.
2.2. DNA and RNA Extraction. D N Aa n dR N Aw e r es i m u l -
taneously extracted from 10mg of liver tissue according
to TEBU Masterpure extraction kit speciﬁcations (TEBU
Masterpure, TebuBio Epicentre, France). DNA/RNA was re-
suspended in 40μLo fT Eb u ﬀer. Nucleic acids were quanti-
ﬁedbyspectrophotometry,andthequalityofRNA/DNAwas
assessedbyPCRwithampliﬁcationofAldolaseBgene,whichHepatitis Research and Treatment 3
Table 2: Distribution of HBV/HCV infection, CTNNB1 mutations
and clinicopathological data according to TP53 mutation status.
MUT TP53
WT TP53 Total R249S Other
TP53 7 2 17 26
CTNNB1 31 2 6
HBsAg positive 5 1 7 13
HBV DNA 6 2 11 19
HCV 1 1 2 4




<32 0 1 0
Cirrhotic NT tissue 3 2 2 7
Age 37.6 ±12.85 34 8 .2 ±12.41
Sex
M5 2 1 3
24†
F0 0 4
MUT = mutant, WT = wildtype,NT = nontumoral tissue, ∗grade is missing
for one WT TP53 case, †age and sex data are missing for two R249S cases.
is constitutively expressed in adult liver. DNA/RNA extracts
were stored at −20◦C.
2.3. TP53 and CTNNB1 Mutations. TP53 mutations were
analyzed by direct, automated sequencing of PCR products
of exons 4 to 11 as described in the IARC TP53 Mutation
Database (http://www-p53.iarc.fr/). R249S mutation was
furtheranalyzedandconﬁrmedbynestedPCR/RFLPofexon
7 as previously described [23]. CTNNB1 mutations in exon
3 (containing common activating mutations) were detected
by Denaturing High Performance Liquid Chromatography
(DHPLC) and sequencing. Brieﬂy, a PCR product was
generated using primers, and 3 to 10μL of this product were
injected into a preheated reverse-phase column (DNASep
Column, Transgenomic) equilibrated by the ion-pairing
agent TEAA 0.1M (Triethylammonium acetate). DNA was
removed from the column by a linear gradient of TEAA
achieved by mixing buﬀer A (TEAA 0.1M) at a constant
ﬂow rate of 0.9mL/min, and buﬀer B (TEAA 0.1M and
acetonitrile 25%) with 2%/minute gradient increase. The
temperature for optimum separation of heteroduplex from
homoduplex was calculated in silico by speciﬁc software
(Transgenomic, San Jose, CA, USA) so that 75% of the
PCR product remains double-stranded. Primer sequences
and temperature used are given in Supplementary Table S2.
2.4. Detection of HBV and HCV. H B VD N Ad e t e c t i o nw a s
performed using a multiplex PCR in highly conserved
regions of surface (S) and core (C) genes. Two S and C
fragments of 118bp and 145bp, respectively, were ampliﬁed
as described elsewhere [24]. PCR products were analyzed by
electrophoresis on 2% agarose gel and ethidium bromide
staining followed by southern blotting and hybridization
with a genomic length [α32P]-dCTP HBV probe. HCV RNA
was detected by seminested RT-PCR (One step RT-PCR Kit,
Qiagen, France) amplifying the 5 - U T Rr e g i o no fH C Va s
described elsewhere [24]. PCR products were analyzed by
electrophoresis on 2% agarose gel and ethidium bromide
staining followed by southern blotting and hybridization
using an HCV [α32P]-dCTP oligo probe.
2.5. HBV Genotyping, Subtyping, and Detection of “a” Loop
Variants. Analysis of S gene provides genotype informa-
tion signiﬁcantly matching with analysis of the entire
genome [25, 26]. We developed a new seminested PCR
amplifying the entire S gene. First reaction was achieved
with primers S HBV123s (5 -tcgaggattggggaccctg-3 )a n d
S HBV848r (5 -ggaatagccccatcttttgg-3 ), round settings were
95◦C (5min); 35 cycles of 95◦C (30sec), 51◦C (30sec),
72◦C (1min); then 72◦C for 10min. Second step used
2μL of ﬁrst reaction and primers S HBV123s and S HBV
778r (5 -gaggtataaagggactcaag-3 ) with similar settings to
the ﬁrst round. 2μL of PCR products were puriﬁed using
standard ExoSap-IT (usb, Staufen, Germany) treatment,
and nucleotide sequences were determined for both strand
by automated, dideoxy-sequencing (sequencer ABIPrism
3100, Perkin Elmer). HBV genotypes and subtypes were
determined thanks to collaboration with the Virological
Department of Swedish Institute for Infectious Disease.
2.6. HBV Basal Core Promoter (BCP) Variant Detection.
DNA extractions of HBV DNA positive patients including T
and NT tissue were tested for HBV BCP variants. Samples
with detectable HBV DNA after nested PCR ampliﬁcation
usingmanufacturer’sprotocolweretestedbylineprobeassay
(INNO-LiPA HBV Precore Research Version, Innogenetics
NV, USA) according to the manufacturer’s instructions [27].
The kit probes were designed to determine the nucleotide
sequences at positions 1762 (A versus T) and 1764 (G versus
A and G versus T) in the BCP region. Determination of Pre-
Core (PC) mutation at HBV codon 1896 (G versus A) was
achieved in the same reaction.
2.7. Immunohistochemistry. Tissue fragments were ﬁxed in
10% buﬀered formalin and paraﬃne m b e d d e da c c o r d -
ing to standard protocols. Deparaﬃnized tissue sections
were labeled using standard protocols with CM1 anti-
body (Ab) (rabbit polyclonal immunoglobulin G anti-
human p53, 1/500, Novacastra Laboratories Ltd., New-
castle, United Kingdom) recognizing all isoforms of
p53 protein. HBV- and/or HCV-positive tumor sec-
tions were labeled independently with a set of anti-
bodies to either HBxAg (rabbit polyclonal Ab used at
5μg/mL) [28] or E2 protein for HCV positive sections
(D4.12.9 monoclonal Ab at 0.2μg/mL) [29]. Fixed anti-
bodies were detected using biotinylated immunoglobulin
G, streptavidine-peroxidase, and diaminobenzidine (Vector










Figure 1: Immunostaining of HCC sections ((a)–(g) × 200, (h) × 400). Accumulation of p53 in HCC with R249S (a) and P278R (b).
Accumulation of HBxAg in hepatocytes of nontumoral (NT) and tumoral (T) tissues of HCC with overt HBV infection (c,d) or occult HBV
infection (e,f). Accumulation of HCV E2 protein in tumor section of overt HBV/HCV (g) or occult HBV/HCV (h) coinfected HCC.
3. Results
3.1. Patients and Tumor Characteristics. Table 1 lists the
clinicopathological characteristics of patients and tumors
analyzed. Age range was from 17 to 73, with a majority
of cases occurring before 50 years of age (62.5%) and a
male/female ratio of 5:1. HBsAg status was positive in 13 of
23patientsforwhomthisinformationwasavailable(56.5%).
Edmondson and Steiner’s grades of tumors were equally
distributed between scores ≥G3 and <G3. Most of adjacent
NT tissues showed an activity score <2 and a ﬁbrosis score
≥2 in the METAVIR scoring system. Most HCC were mainly
trabecular (69.3%). Pleiomorphic or pseudoglandular types
represented 11.5% and 7.7%, respectively. In 3 cases, high
levels of necrosis or tissue degradation were observed
precluding the precise assessment of HCC morphology.
Cirrhosis was diagnosed in 7 of the 20 NT tissues.
3.2.MutationsinTP53andCTNNB1Genes. TP53mutations
were detected in 9 cases (34.6%), with a high proportion
of R249S (present in 7 cases, 77.8%). This mutation was
associatedwithalowlevelofp53nuclearaccumulationinthe
tumor (<10% of cells stained, 6 cases) or with retention of
p53 in the cytoplasm (1 case) (Figure 1(a)). Immunostaining
of R249S-positive sections with an antibody to aﬂatoxin-
DNA adducts was negative (data not shown). Two other
mutations were at codon 278 (CCC to CTC, P278R)a n d
codon 331 (CAG to CAT, G331H). P278R falls within the




































Figure 3: Distribution of TP53 and CTNNB1 mutations in overt
andoccultHBV-infectedcases.AllHBV-positivecaseswerecounted
from Table S2. Five cases with nonavailable CTNNB1 status were
excluded, giving a total number of 17 cases. Total numbers are
indicated in brackets. Six cases were mutated in either CTNNB1 or
in TP53 (R249S) and 3 of them harbored both mutations. Finally,
8 cases were wildtype for both genes or mutated at other codons in
TP53.
of transactivation activity towards 8 diﬀerent p53-dependent
promoters in yeast functional assays [30]. This mutation was
associatedwithaccumulationoftheproteinin10–20%ofthe
cells (Figure 1(b)). In contrast, R331H falls in exon 9 next
to the p53 oligomerization domain and does not appear to
signiﬁcantly suppress p53 transactivating capacity in a yeast
functional assay [30]. This mutation does not result in p53
accumulation (data not shown). Three specimens exhibited
p53 accumulation despite the presence of wild-type (WT)
TP53 sequences (data not shown).
Sixmutationsinexon3ofCTNNB1(23%)werefoundby
DHPLC and direct sequencing. Mutations were exclusively
found in tumors at codons specifying serines or threonines
in the N-terminus. These phosphorylation sites are part of
the GSK3-β box. Four out of the six tumors with CTNNB1
mutation also had a TP53 mutation (three R249S and one
P278R)( T a b l e2).
3.3. Molecular Patterns of Hepatitis Viral Infections. HBV
DNA was detected in both T and NT specimens of 19 HCC
patients (73%), whereas 4 HCC cases (15.4%) were positive
for HCV RNA, 3 out of 4 being coinfected with HBV. When
comparing HBV DNA with HBsAg status, 11 cases were
positive for both, 5 cases were positive for DNA only (occult
infection), and 2 cases were positive for HBsAg only (note
that nontumor tissue was not available for these two cases).
Thus, of the 10HBsAg negative cases, 5 harbored HBV DNA,
indicating a proportion of 50% of occult infections among
HBsAg negative patients. Only one of these 5 patients with
occult HBV infection was positive for HCV. Occult infection
was detected in all age groups, but was more frequent in
patients over 51 (3/5, 60%) than under 50 (3/14, 21.4%)
(Figure 2).
Preampliﬁcation of Pre-C/C region prior to INNO-LIPA
reverse hybridization was successfully performed in 9 out of
19 HBV DNA-positive specimens. The BCP double variant
A1762/T1764 was found in 7 cases (77.8%). Distribution
of BCP double variant and wild-type HBV populations
was not restricted to tumoral tissues. The PC variant was
detected in the NT tissue of one patient (data not shown, see
Supplementary Table S1).
The entire S gene was sequenced in 11/19 HBV DNA-
positive specimens. The two main HBV genotypes were
C and B, found, respectively, in 81.8% (9/11) and 18.2%
(2/11) of patients. Several mutations were detected in the
region corresponding to the “a” loop determinant (residues
from 124 to 147) [31]. Two mutations have been previously
described as “escape” mutations in vaccinated subjects
(G145R and I126N)[ 32, 33]. Both were found in patients
with occult HBV infection (Supplementary Figure S3). In
specimen 26, we detected a double mutation A126I/P127T,
which has not been reported before.
HBxAg was strongly expressed in 80% of HBV-positive
cases. The pattern of HBxAg accumulation diﬀered between
T and NT tissues. In the latter, we observed cytoplasmic
accumulation in 15–60% of cells, with nuclear accumulation
in some hepatocytes (Figure 1(c)). In the former, accumu-
lation was stronger in regeneration nodules and nuclear
compartments were strongly stained (Figure 1(d)).The same
staining pattern was observed in either overt or occult HBV
infections (Figures 1(e) and 1(f)).
3.4. Concordance between Viral Infection, Tumor Morphology,
and Mutations in TP53 or CTNNB1. Tumors were classiﬁed
according to their HBV status as occult, overt, or negative
HBV infection. There was no diﬀerence in relation to age,
sex, tumor grade, activity/ﬁbrosis scores, and incidence of
HCV infection between the three groups (Table 3). HBV
genotypes and PC/BCP mutations were equally distributed
within the three groups. However, trabecular morphology
was more common among HBV-infected subjects, regardless
of occult or overt status. Regarding mutations, CTNNB16 Hepatitis Research and Treatment




infections n = 5
Negative for both
HBsAg and HBV
DNA n = 5
Total
TP53
R249S 50 0 5
Other mutation 1 1 0 2
WT 7 4 5 16
CTNNB1
MUT 3 2 0 5
WT 7 3 4 14
HCV 2 1 1 4
Sex
M1 3 4 3 2 0
F0 1 2 3
Grade
≥37 2 2 1 1
<36 3 3 1 2
HCC morphology
Trabecular 11 5 2 18
Pleiomorphic 2 0 1 3
Pseudoglandular 1 0 1 2
Necrosis 1 0 2 3
Age 43.2 ±12.12 51.4 ±15.24 9 .4 ±13.7
WT = wildtype, MUT = mutant, ∗three HBV-DNA positive cases with missing data on serology were omitted in this table, †CTNNB1 was not ampliﬁable in
four cases, three cases with overt HBV infection and one HBV-negative case.
mutation rates did not diﬀer between the three groups
but R249S was strongly associated with overt HBV infec-
tion. Accumulation of p53 in tumors with wild-type TP53
sequenceswasidentiﬁedexclusivelyinHBV-negativetumors,
one of which was HCV RNA-positive (see Supplementary
TableS1).Overall,theseresultsdonotsubstantiatethatTP53
and CTNNB1 mutations fall in distinct subtypes of HCC
(Figure 3). However, they conﬁrm the strong concordance
between R249S and overt chronic HBV infection.
4. Discussion
Most of the current knowledge on the mechanisms of
HCC pathogenesis is based on studies developed in Western
Europe or in the US. However, these two regions hold less
than25%oftheworldannualcasesofHCC.Giventhestrong
geographic diﬀerences in the distribution of risk factors,
studies in other areas are mandatory to obtain a more precise
picture of the complexity of interactions between mutations
and viral infections. In particular, countries such as Thailand
represent interesting areas because of the coexistence of
multiple viral, lifestyles, dietary, and environmental risk
factors. While detailed assessment of these factors is beyond
the scope of this work and will require extensive case-
control comparison studies, the present pilot study shows
notable diﬀerences when compared with the results of
studies in Western countries. These diﬀerences are (1)
the high prevalence of R249S, which is unexpected in a
country where exposure to aﬂatoxin through the diet is
considered as relatively low; (2) the high prevalence of HBV
infections (80.8%), taking into account occult infections;
(3) the relatively modest role of HCV infection, which is
present in only a small proportion of the cases, mostly in
conjunction with HBV infection; (4) the coexistence of TP53
and CTNNB1 mutations in a proportion of the cases (3 cases
among the 11 with either TP53 or CTNNB1 mutations),
inconsistent with a systematic mutual exclusion between two
distinct pathways of carcinogenesis.
There is evidence that R249S is caused by direct adduc-
tion of aﬂatoxin metabolites on the third base of codon 249.
This mutation is very speciﬁc for HCC in high incidence
areas of China or sub-Saharan Africa, and there is a good
overall concordance between the prevalence of this mutation
in HCC and the levels of exposure to aﬂatoxins in the
general population. In Thailand, the population exposure is
considered as low to intermediate. In 1993 a study conducted
on a series of 15 HCC cases from central Thailand reported
only one R249S (6.7%) [3]. However, more recently Kuang
and collaborators [4] reported a prevalence of R249S of
24% in HCC cases from Chiang Mai in the Northern part
of Thailand. Our results (26.9%) are compatible with theirHepatitis Research and Treatment 7
results [4] and suggest that exposure to aﬂatoxin in the
general population of Thailand may be higher than pre-
viously recognized, despite absence of detectable aﬂatoxin-
DNA adducts in liver tissues of patients. In line with this
notion, a recent assessment of aﬂatoxin contamination in
Thailandintwobasicdietarycomponents,cornandpeanuts,
has shown mean aﬂatoxin levels which are 3 to 5 times
higher than the Thailand Regulation limit [34]. Although
these levels are about 4 times lower than those reported in
populationswhereHCCishighlyprevalent,theysuggestthat
aﬂatoxin may still play an important role as a cofactor with
chronic HBV carriage in causing HCC in Thailand.
Patients with R249S were all HBV carriers, and they
tended to be younger than those without mutation or with
mutationatothercodons.Thispatternissimilartotheoneof
HCC in areas of high HBV endemicity combined with high
exposure to aﬂatoxin [23]. Interestingly, we noted that occult
HBV infection represented 27.8% of all HBV-positive cases,
compatiblewithpreviousstudiesinChina(26%,n = 132)or
Taiwan (29%, n = 31) [35, 36]. None of these cases harbored
an R249S mutation. These observations are consistent with
the hypothesis that occult HBV infection may play a causal
role in the pathogenesis of HCC [37, 38].
In agreement with previous studies [39], HBV geno-
type C was predominant (81.8%), followed by genotype
B (18.2%). The BCP double-mutation 1762T/1764A was
detected in all of the 6 patients analyzed, either in the tumor
(1 case), the adjacent tissue (2 cases), or both (3 cases).
Thus, despite published results suggesting that this mutation
may be associated with increased severity of infection and
cirrhosis,ourresultsdonotsuggestselectionofthemutation
during tumor progression.
Occult hepatitis may result from diﬀerent mechanisms
includingdefectiveHBsAgexpression(dueto,e.g.,structural
or regulatory mutations in S gene [24, 40]) or inhibition
of HBV replication due to HCV co-infection [41, 42]. Of
t h eSg e n es e q u e n c e sa n a l y z e di nt h ep r e s e n ts t u d y ,t w o
exhibited escape mutations in the antigenic determinant “a”
(G145R + I126N for THAI10 and G145R for THAI27); while
we did not detect any nucleotide change in the S sequence
of the 7 cases with overt HBV infection. A third sequence
(THAI26) exhibited a double nucleotide substitution I126A
+ P127T that has not been reported so far. The consequences
of this mutation are unknown, although the contiguous
isoleucine to proline substitution may induce structural
changes explaining the absence of HBsAg response.
In our study, HCV infection rate is 5.25-fold lower
than HBV, conﬁrming a low to intermediate contribution
of HCV in HCC development. However, it is important to
note that a strong accumulation of HCV envelope protein
was detected in regeneration nodules of either mono- or
coinfected samples (Figures 3(g) and 3(h)), suggesting active
replication of the virus within tumor cells.
Studies on genetic alterations in HCC identifying two
distinct pathways for hepatocarcinogenesis lead to consider
that mutations in TP53 and CTNNB1 rarely occur simulta-
neously in liver tumors. However, this model is essentially
based on results obtained on tumors from Western countries
and it is unclear whether it also applies to HCC in a context
of aﬂatoxin exposure. Our results suggest that CTNNB1
mutations may be present in HBV-infected tumors together
with R249S. It should be considered that, in the context
of aﬂatoxin exposure and chronic HBV infection, R249S
is likely to occur as an early event, which may contribute
to genetic and chromosomal instability and thus facilitate
cell proliferation and survival in the hostile conditions that
result of the combined exposure. This, in turn, may increase
the risk of acquisition of mutations in many other genes
including CTNNB1. In contrast, in a context of low aﬂatoxin
exposure, events other than TP53 mutations are likely to
take place as early steps. CTNNB1 mutations may represent
such an early event, which may be conditional for the entire
sequence of subsequent events during tumor progression. In
such a scenario, TP53 mutations may occur as a late event in
a subset of cancers. Thus, we propose that HCC that arises
in a context of aﬂatoxin exposure may develop according
to a speciﬁc sequence of genetic events that may include
both TP53 and CTNNB1 mutations. The identiﬁcation of
key steps in this sequence will require extensive comparative
studiesongenealterationandexpressionpatternsfromHCC
from diﬀerent geographic areas and etiological contexts.
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